Loading
Life sciences · Journal article
Journal of Acute Care Trauma and Emergency Medicine · June 29, 2026
Raises a question worth testing. It does not answer one.
This narrative review describes an emerging hypothesis linking oral dysbiosis and periodontal disease to Alzheimer's disease pathogenesis through proposed mechanisms including neuroinflammation, blood–brain barrier dysfunction, and microbial components in neural tissue. The evidence base comprises primarily animal models and in vitro studies, with associational human data (periodontitis, tooth loss, and faster cognitive decline); causation in humans remains unproven, and interventional trials demonstrating neurological benefit from oral health modification are lacking.
Narrative review. Published literature on oral dysbiosis, periodontal disease, and Alzheimer's disease, including animal models, in vitro studies, observational human studies, and mechanistic investigations.. Intervention: Oral health modification or treatment of periodontal disease (as inferred from discussion; no specific intervention trials detailed)..
Oral microbiome comprises >700 species organized in biofilms; periodontal disease is highly prevalent in adults and can drive sustained systemic inflammation. Porphyromonas gingivalis and its gingipains have been reported in AD brain samples and experimental models, with downstream effects on amyloid-β dynamics, tau processing, and microglial activation. Increasing evidence has linked periodontitis and tooth loss with faster cognitive decline and higher dementia risk.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should be aware that oral health represents a plausible, potentially modifiable factor in AD risk biology, but current evidence does not yet support specific oral interventions as a standard dementia prevention or treatment strategy. Further longitudinal and interventional clinical research is needed before clinical recommendations can be made.
A narrative review synthesizing mechanistic and associational evidence from animal models, in vitro studies, and observational human data, identifying oral dysbiosis as a plausible but unproven contributor to Alzheimer's disease pathogenesis without definitive human causation or intervention trials.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should be aware that oral health represents a plausible, potentially modifiable factor in AD risk biology, but current evidence does not yet support specific oral interventions as a standard dementia prevention or treatment strategy. Further longitudinal and interventional clinical research is needed before clinical recommendations can be made.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Alzheimer's disease (AD) affects ~55 million people globally and is projected to rise steeply with population ageing.While genetic risk and amyloid biology remain central to AD research, the limited clinical success of anti-amyloid strategies has encouraged exploration of additional contributors, including chronic peripheral infections.The oral microbiome comprises >700 species organized in biofilms, and periodontal disease-highly prevalent in adults-can drive sustained systemic inflammation.Increasing evidence has linked periodontitis and tooth loss with faster cognitive decline and higher dementia risk, raising the possibility of an oral-brain connection.This narrative review summarized literature (PubMed, Scopus, Google Scholar; January 2000-December 2024) on oral dysbiosis and AD, prioritizing systematic reviews and human studies while using animal and laboratory data to explain mechanisms.Proposed pathways include cytokine-mediated neuroinflammation, blood-brain barrier dysfunction, and the presence of microbial components in neural tissue.In particular, Porphyromonas gingivalis and its gingipains have been reported in AD brain samples and experimental models, with downstream effects on amyloid-β dynamics, tau processing, and microglial activation.Other organisms, including Treponema species, Fusobacterium nucleatum, Actinomyces naeslundii, Candida albicans, and herpesviruses (e.g., HSV-1), have been discussed as potential contributors through inflammatory and oxidative stress pathways.However, much mechanistic support is derived from animal or in-vitro studies, which cannot be equated with human causation.Reverse causality and confounding by frailty, nutrition, and socioeconomic factors remain important concerns, and interventional human trial evidence demonstrating neurological benefit from modifying oral health is still limited.Overall, oral health represents a plausible, potentially modifiable factor relevant to AD risk biology, warranting cautious interpretation and further longitudinal and interventional clinical research.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.